Literature DB >> 25339023

Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer.

Elif Erturk1, Gulsah Cecener, Volkan Polatkan, Sehsuvar Gokgoz, Unal Egeli, Berrin Tunca, Gulcin Tezcan, Elif Demirdogen, Secil Ak, Ismet Tasdelen.   

Abstract

Although genetic markers identifying women at an increased risk of developing breast cancer exist, the majority of inherited risk factors remain elusive. Mutations in the BRCA1/BRCA2 gene confer a substantial increase in breast cancer risk, yet routine clinical genetic screening is limited to the coding regions and intron- exon boundaries, precluding the identification of mutations in noncoding and untranslated regions. Because 3' untranslated region (3'UTR) polymorphisms disrupting microRNA (miRNA) binding can be functional and can act as genetic markers of cancer risk, we aimed to determine genetic variation in the 3'UTR of BRCA1/BRCA2 in familial and early-onset breast cancer patients with and without mutations in the coding regions of BRCA1/ BRCA2 and to identify specific 3'UTR variants that may be risk factors for cancer development. The 3'UTRs of the BRCA1 and BRCA2 genes were screened by heteroduplex analysis and DNA sequencing in 100 patients from 46 BRCA1/2 families, 54 non-BRCA1/2 families, and 47 geographically matched controls. Two polymorphisms were identified. SNPs c.*1287C>T (rs12516) (BRCA1) and c.*105A>C (rs15869) (BRCA2) were identified in 27% and 24% of patients, respectively. These 2 variants were also identified in controls with no family history of cancer (23.4% and 23.4%, respectively). In comparison to variations in the 3'UTR region of the BRCA1/2 genes and the BRCA1/2 mutational status in patients, there was a statistically significant relationship between the BRCA1 gene polymorphism c.*1287C>T (rs12516) and BRCA1 mutations (p=0.035) by Fisher's Exact Test. SNP c.*1287C>T (rs12516) of the BRCA1 gene may have potential use as a genetic marker of an increased risk of developing breast cancer and likely represents a non-coding sequence variation in BRCA1 that impacts BRCA1 function and leads to increased early-onset and/or familial breast cancer risk in the Turkish population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339023     DOI: 10.7314/apjcp.2014.15.19.8319

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  10 in total

1.  Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A.

Authors:  Wanjun Li; Guoyin Li; Zhigang Fan; Tao Liu
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

2.  Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.

Authors:  Amandine I Garcia; Monique Buisson; Francesca Damiola; Chloé Tessereau; Laure Barjhoux; Carole Verny-Pierre; Valérie Sornin; Marie-Gabrielle Dondon; Séverine Eon-Marchais; Olivier Caron; Marion Gautier-Villars; Isabelle Coupier; Bruno Buecher; Philippe Vennin; Muriel Belotti; Alain Lortholary; Paul Gesta; Catherine Dugast; Catherine Noguès; Jean-Pierre Fricker; Laurence Faivre; Dominique Stoppa-Lyonnet; Nadine Andrieu; Olga M Sinilnikova; Sylvie Mazoyer
Journal:  Eur J Hum Genet       Date:  2016-01-20       Impact factor: 4.246

3.  rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility.

Authors:  Jingjing Cao; Chenglin Luo; Rui Yan; Rui Peng; Kaijuan Wang; Peng Wang; Hua Ye; Chunhua Song
Journal:  Med Oncol       Date:  2016-11-02       Impact factor: 3.064

4.  Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx.

Authors:  Lijun Zhu; Erich M Sturgis; Hua Zhang; Zhongming Lu; Ye Tao; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2017-07-07       Impact factor: 7.396

5.  Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.

Authors:  G Cecener; G Guney Eskiler; U Egeli; B Tunca; A Alemdar; S Gokgoz; I Tasdelen
Journal:  Mol Biol Rep       Date:  2016-08-29       Impact factor: 2.316

6.  MiR-300 regulate the malignancy of breast cancer by targeting p53.

Authors:  Xiao-Heng Xu; Da-Wei Li; Hui Feng; Hong-Mei Chen; Yan-Qiu Song
Journal:  Int J Clin Exp Med       Date:  2015-05-15

7.  LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations.

Authors:  Lucas Lochovsky; Jing Zhang; Yao Fu; Ekta Khurana; Mark Gerstein
Journal:  Nucleic Acids Res       Date:  2015-08-24       Impact factor: 16.971

Review 8.  SNPs in miRNAs and Target Sequences: Role in Cancer and Diabetes.

Authors:  Yogita Chhichholiya; Aman Kumar Suryan; Prabhat Suman; Anjana Munshi; Sandeep Singh
Journal:  Front Genet       Date:  2021-12-01       Impact factor: 4.599

9.  Genetic Variants Associated with Clinicopathological Profiles in Sporadic Breast Cancer in Sri Lankan Women.

Authors:  Nirmala Dushyanthi Sirisena; Adebowale Adeyemo; Anchala Ishani Kuruppu; Nilakshi Samaranayake; Vajira Harshadeva Weerabaddana Dissanayake
Journal:  J Breast Cancer       Date:  2018-06-20       Impact factor: 3.588

10.  Genetic Variants in the 3'UTR of BRCA1 and BRCA2 Genes and their Putative Effects on the microRNA Mechanism in Hereditary Breast and Ovarian Cancer.

Authors:  María Marisela Sánchez-Chaparro; Idalia Garza-Veloz; Omar Alejandro Zayas-Villanueva; Margarita L Martinez-Fierro; Iván Delgado-Enciso; Mayra Alejandra Gomez-Govea; Laura Elia Martínez-de-Villarreal; Diana Reséndez-Pérez; Iram Pablo Rodríguez-Sánchez
Journal:  Diagnostics (Basel)       Date:  2020-05-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.